Abstract
Goodpasture syndrome is a life‐threatening autoimmune kidney and pulmonary disease that is characterized by pulmonary hemorrhage, renal failure, and the presence of autoantibodies against glomerular basement membrane (GBM) by indirect fluorescent antibody (IFA) techniques. In 1988, these antibodies were found to be specific for the noncollagen region of the α3 collagen IV chain. The antigen is characterized by a restricted tissue distribution occurring mainly in the kidneys and lungs. Specific enzyme immunoassays (EIAs) for anti‐GBM have now been developed for in vitro diagnostic use in the laboratory. Our objective in this study was to compare the results obtained using four different EIAs for detecting anti‐GBM IgG antibody with those using the standard IFA method using tissue from human kidney. Thirty‐two patients with suspected Goodpasture syndrome, and 10 control sera were included in the study. GBM EIAs were purchased from or donated by the following vendors: Scimedx Corporation (Denville, NJ), INOVA Diagnostics (San Diego, CA), The Binding Site (Birmingham, England), and Wieslab (distributed by DiaSorin, Inc., Stillwater, MN). Percent agreement, sensitivity, and specificity were calculated for each EIA as compared to IFA. The results were as follows: Binding Site: 83.3, 100.0, and 72.0%; Wieslab: 95.2, 94.1, and 96.0%; INOVA: 96.2, 100.0, and 92.3%; and Scimedx: 81.0, 100.0, and 68.0%. We conclude that the INOVA and Wieslab GBM IgG EIAs compared well with the standard GBM IFA method using tissue from human kidney. The Scimedx and Binding Site EIAs had eight and seven false‐positive results, respectively, when compared to GBM IFA using human kidney. The authors recommend conducting thorough evaluations of EIAs that screen for anti‐GBM antibody before their implementation in the clinical laboratory. We also recommend confirming GBM EIA‐positive sera by the standard IFA method using tissue from human kidney. J. Clin. Lab. Anal. 16:143–145, 2002. © 2002 Wiley‐Liss, Inc.
Keywords: glomerular basement membrane (GBM), Goodpasture syndrome, IgG, autoimmune kidney disease, enzyme immunoassay (EIA), indirect fluorescent antibody (IFA)
REFERENCES
- 1. Saus J, Wieslander J, Langeveld JP, Quinones S, Hudson BG. 1988. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 263:13374–13380. [PubMed] [Google Scholar]
- 2. Wieslander J. 1990. The Goodpasture antigen. Contrib Nephrol 80:56–67. [DOI] [PubMed] [Google Scholar]
- 3. Weber M, Pullig O, Kohler H. 1990. Distribution of Goodpasture antigens within various human basement membranes. Nephrol Dial Transplant 5:87–93. [DOI] [PubMed] [Google Scholar]
- 4. Derry CJ, Pusey CD. 1994. Tissue‐specific distribution of the Goodpasture antigen demonstrated by 2‐D electrophoresis and western blotting. Nephrol Dial Transplant 9:355–361. [PubMed] [Google Scholar]
- 5. Mattay RA, Bromberg SI, Putman CE. 1980. Pulmonary renal syndromes—a review. Yale J Biol Med 53:497–523. [PMC free article] [PubMed] [Google Scholar]
- 6. Young KR Jr. 1989. Pulmonary‐renal syndromes. Clin Chest Med 10:655–675. [PubMed] [Google Scholar]
- 7. Tarantino A, Barbiano di Belgiojoso G, Durante A, Imbasciati E, Bazzi C. 1973. Immuno‐histological characterization of glomerular nephropathies evaluated by direct and indirect methods. Minerva Nefrol 20:199–210. [PubMed] [Google Scholar]
- 8. Schneider W, Manger T, Porstmann T. 1986. Immunologic diagnosis of glomerulonephritis by basement membrane antibodies. Z Urol Nephrol 79:53–57. [PubMed] [Google Scholar]
- 9. Savage CO, Noel LH, Crutcher E, Price SR, Grunfeld JP, Lockwood CM. 1989. Hereditary nephritis: immunoblotting studies of the glomerular basement membrane. Lab Invest 60:613–618. [PubMed] [Google Scholar]
- 10. Weber MF, Andrassy K, Pullig O, Koderisch J, Netzer K. 1992. Antineutrophil‐cytoplasmic antibodies and antiglomerular basement antibodies in Goodpasture’s syndrome and Wegener’s granulomatosis. J Am Soc Nephrol 2:1227–1234. [DOI] [PubMed] [Google Scholar]